Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMNN

Imunon, Inc.

Healthcare · Biotechnology

$0.91

Up+$0.01 (+0.78%)

Updated Nov 5, 2026, 10:59 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.46M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.81 – $3.30
Volume
22.06K
Avg. volume
90.7K

Price performance · IMNN

IMNN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

IMNN closed at $0.91 after 21 trading sessions, down 20.44% for the selected period.

Last close
$0.91
Period change
-20.44%
Period low
$0.83
Period high
$1.25
Daily close
View OHLC price history
IMNN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.97$0.9789$0.8801$0.90722.06K
Nov 3, 2026$0.87$0.95$0.867$0.9061.89K
Nov 2, 2026$0.905$0.92$0.84$0.870172.72K
Oct 30, 2026$0.84$1.00$0.84$0.91132.52K
Oct 29, 2026$0.859$0.875$0.8101$0.833211.78K
Oct 28, 2026$0.86$0.8749$0.82$0.8301195.02K
Oct 27, 2026$0.9525$1.01$0.83$0.8762542.69K
Oct 26, 2026$1.25$1.27$1.185$1.2339.38K
Oct 23, 2026$1.25$1.25$1.16$1.23522.65K
Oct 22, 2026$1.21$1.275$1.17$1.2534.86K
Oct 21, 2026$1.03$1.209$1.01$1.19272.43K
Oct 20, 2026$0.982$1.005$0.98$1.00544.53K
Oct 19, 2026$0.99$1.02$0.98$0.98593.8K
Oct 16, 2026$1.05$1.05$1.01$1.0255.51K
Oct 15, 2026$1.03$1.07$1.03$1.0639.19K
Oct 14, 2026$1.08$1.08$1.03$1.0418.97K
Oct 13, 2026$1.07$1.08$1.0069$1.0739.68K
Oct 12, 2026$1.06$1.10$1.03$1.0742.48K
Oct 9, 2026$1.09$1.12$0.96$1.08238.86K
Oct 8, 2026$1.15$1.175$1.03$1.07135.36K
Oct 7, 2026$1.12$1.16$1.10$1.14107.64K

Latest IMNN news

The latest Smart Investors Daily articles mentioning IMNN.

Stock researchCompany · Overview

IMNN research

Overview

Company profile and research snapshot.

Company profile

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
IMNN recent ratings
DateFirmRatingTarget
Apr 17, 2026Maxim GroupBuy—
May 19, 2025D. Boral CapitalHold—
May 13, 2025D. Boral CapitalBuy—
May 7, 2025D. Boral CapitalBuy—
Mar 26, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

IMUNON Announces Strategic Sale of ThermoDox®

Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON's Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001 LAWRENCEVILLE, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an agre

Yahoo · Oct 8, 2026

IMUNON to Participate in Upcoming Investor Conferences

LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026Date: October 12 - 14, 2026Location: Hard Rock Hotel, New York, NYPresentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a com

Yahoo · Oct 1, 2026

IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer

By David Bautz, PhD NASDAQ: IMNN READ THE FULL IMNN RESEARCH REPORT Business Update R&D Day Highlights IMNN-001 in Advanced Ovarian Cancer On September 23, 2026, Imunon, Inc. (NASDAQ: IMNN) held an R&D Day to discuss the IMNN-001 program, which included a discussion on the use of localized IL-12 in cancer therapy, translational data that showed IMNN-001 is preferentially taken up by

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By